EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Alterations in Mitochondrial Function in Pulmonary Vascular Diseases

Samar Farha iD, Kewal Asosingh, Paul M Hassoun, John Barnard, Suzy Comhair, Andrew Reichard, Nicholas Wanner, Milena Radeva, Micheala A Aldred, Gerald J Beck, Erika Berman-Rosenzweig, Barry A Borlaug und 14 weitere

Antioxidants & Redox Signaling · 2025-03 · 42 (7-9) · 361-377

DOI: 10.1089/ars.2024.0557 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antioxidants & Redox Signaling, online erschienen am 07.03.2025. Verfasst von Samar Farha und 25 weiteren Autor:innen. Beteiligte Einrichtung: Integrated Hospital-Care Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Mitochondria, Hypertension, Pulmonary. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Alterations of mitochondrial bioenergetics and arginine metabolism are universally present and mechanistically linked to pulmonary arterial hypertension (PAH), but there is little knowledge of arginine metabolism and mitochondrial functions across the different pulmonary hypertension (PH) groups. We hypothesize that abnormalities in mitochondrial functions are present across all PH groups and associated with clinical phenotypes. We test the hypothesis in PH patients and healthy controls from the Pulmonary Vascular Disease Phenomics Program cohort, who had comprehensive clinical phenotyping and follow-up for at least 4 years for death or transplant status. Mitochondrial transmembrane potential, superoxide production, and mass were measured by flow cytometry in fresh platelets. Metabolomics analysis was performed on plasma samples. Global arginine bioavailability was calculated as the ratio of arginine/(ornithine+citrulline).

Results

Global arginine bioavailability is consistently lower than controls in all PH groups. Although the mitochondrial mass is similar across all PH groups and controls, superoxide production and transmembrane potential vary across groups. Mitochondrial superoxide is higher in group 1 PAH and lowest in group 3 compared with other groups, while transmembrane potential is lower in group 1 PAH than controls or group 3. The alterations in mitochondrial functions of group 1 PAH are associated with changes in fatty acid metabolism. Mitochondrial transmembrane potential in group 1 PAH is associated with transplant-free survival.

Conclusion

While alterations in mitochondrial function are found in all PH groups, group 1 PAH has a unique mitochondrial phenotype with greater superoxide and lower transmembrane potential linked to fatty acid metabolism, and clinically to survival. Antioxid. Redox Signal. 42, 361–377.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitochondriaHypertension, PulmonaryHumansFemaleMaleMiddle AgedMembrane Potential, MitochondrialArginineSuperoxidesAdultMetabolomics

Stichwörter der Autor:innen

arginine metabolismmitochondriapulmonary hypertensionsuperoxide productiontransmembrane potential

Substanzen

ArginineSuperoxides

Autor:innen und Institutionen

  • Integrated Hospital-Care Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Lerner Research Institute, Cleveland Clinic, Ohio, USA.
  • Division of Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, Maryland, USA.
  • Department of Medicine, Indiana University School of Medicine Indianapolis, Indianapolis, Indiana, USA.
  • Department of Pediatrics and Medicine, Columbia University, New York, New York, USA.
  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Samar Farha

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Farha, S., Asosingh, K., Hassoun, P. M., Barnard, J., Comhair, S., Reichard, A., Wanner, N., Radeva, M., Aldred, M. A., Beck, G. J., Berman-Rosenzweig, E., Borlaug, B. A., Finet, J. E., Frantz, R. P., Grunig, G., Hemnes, A. R., Hill, N., Horn, E. M., Jellis, C., …, & PVDOMICS Study Group (2025). Alterations in Mitochondrial Function in Pulmonary Vascular Diseases. Antioxidants & Redox Signaling, 42(7-9), 361-377. https://doi.org/10.1089/ars.2024.0557

Vancouver

Farha S, Asosingh K, Hassoun PM, Barnard J, Comhair S, Reichard A, et al. Alterations in Mitochondrial Function in Pulmonary Vascular Diseases. Antioxidants & Redox Signaling. 2025;42(7-9):361-377. doi:10.1089/ars.2024.0557

BibTeX
@article{Farha2025,
  author = {Farha, Samar and Asosingh, Kewal and Hassoun, Paul M and Barnard, John and Comhair, Suzy and Reichard, Andrew and Wanner, Nicholas and Radeva, Milena and Aldred, Micheala A and Beck, Gerald J and Berman-Rosenzweig, Erika and Borlaug, Barry A and Finet, J Emanuel and Frantz, Robert P and Grunig, Gabriele and Hemnes, Anna R and Hill, Nicholas and Horn, Evelyn M and Jellis, Christine and Leopold, Jane A and Mehra, Reena and Park, Margaret M and Rischard, Franz P and Tang, W H Wilson and Erzurum, Serpil C and PVDOMICS Study Group, PVDOMICS Study Group},
  title = {Alterations in Mitochondrial Function in Pulmonary Vascular Diseases},
  journal = {Antioxidants & Redox Signaling},
  year = {2025},
  volume = {42},
  number = {7-9},
  pages = {361--377},
  doi = {10.1089/ars.2024.0557}
}
Kostenlos starten →